Literature DB >> 16465179

Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting.

Arich Ryan Reynolds1, Natasha Kyprianou.   

Abstract

The intricate balance maintained between cell growth and proliferation factors and apoptosis-inducing factors is fundamental to the regulation of prostate growth. Disruptions in this homeostasis often trigger the loss of apoptosis and the over-expression of factors promoting cell survival and proliferation, inevitably leading to tumorigenesis and cancer. Deregulation of prostate growth during prostate cancer development and progression is characterized by apoptotic evasion, uncontrolled proliferation, and increased invasive potential. Thus, in advanced stages of disease progression, surviving prostate tumour cells acquire the ability to migrate and invade heterotopic tissues, with the bone and lymph nodes being the most common sites for human prostate cancer metastasis. The challenges in the implementation of effective therapeutic strategies for the treatment of advanced metastatic prostate cancer reflect the multidimensional nature and functional significance of antiapoptotic pathways in the emergence of therapeutic resistance of prostate tumours. In this chapter, we discuss the current understanding of the molecular mechanisms governing growth factor signalling pathways with often overlapping functions that contribute to loss of apoptosis control and activation of cell proliferation towards aggressive prostate tumorigenic growth and metastatic behaviour. While a full understanding of the prosurvival characteristics of these growth factor pathways is still evolving, the impact that growth factors such a epidermal growth factor and transforming growth factor-beta can be recognized by the vigorous attempts at therapeutic targeting of their key signalling steps.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16465179      PMCID: PMC1751493          DOI: 10.1038/sj.bjp.0706635

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  100 in total

1.  Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells.

Authors:  Lamonica V Stewart; Nancy L Weigel
Journal:  Prostate       Date:  2005-06-15       Impact factor: 4.104

2.  Mandibular defect repair by TGF-beta and IGF-1 released from a biodegradable osteoconductive hydrogel.

Authors:  Samer Srouji; Adi Rachmiel; Israel Blumenfeld; Erella Livne
Journal:  J Craniomaxillofac Surg       Date:  2005-04       Impact factor: 2.078

3.  HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas.

Authors:  Michael J Gray; Jing Zhang; Lee M Ellis; Gregg L Semenza; Douglas B Evans; Stephanie S Watowich; Gary E Gallick
Journal:  Oncogene       Date:  2005-04-28       Impact factor: 9.867

Review 4.  Endogenous inhibitors of angiogenesis.

Authors:  Pia Nyberg; Liang Xie; Raghu Kalluri
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

5.  Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.

Authors:  Anton Stangelberger; Andrew V Schally; Jozsef L Varga; Brian D Hammann; Kate Groot; Gabor Halmos; Ren-Zhi Cai; Marta Zarandi
Journal:  Prostate       Date:  2005-08-01       Impact factor: 4.104

Review 6.  The biology of VEGF and its receptors.

Authors:  Napoleone Ferrara; Hans-Peter Gerber; Jennifer LeCouter
Journal:  Nat Med       Date:  2003-06       Impact factor: 53.440

Review 7.  Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton.

Authors:  J Bogdanos; D Karamanolakis; R Tenta; A Tsintavis; C Milathianakis; C Mitsiades; M Koutsilieris
Journal:  Endocr Relat Cancer       Date:  2003-06       Impact factor: 5.678

8.  FGF8 isoform b expression in human prostate cancer.

Authors:  V J Gnanapragasam; M C Robinson; C Marsh; C N Robson; F C Hamdy; H Y Leung
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

9.  PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation.

Authors:  Jill K Slack-Davis; Scott T Eblen; Maja Zecevic; Scott A Boerner; Adel Tarcsafalvi; H Bruce Diaz; Mark S Marshall; Michael J Weber; J Thomas Parsons; Andrew D Catling
Journal:  J Cell Biol       Date:  2003-07-21       Impact factor: 10.539

10.  Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction.

Authors:  J V Partin; I E Anglin; N Kyprianou
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

View more
  25 in total

1.  The effects of self-assembling peptide RADA16 hydrogel on malignant phenotype of human hepatocellular carcinoma cell.

Authors:  Hong Song; Yun-Zhu Han; Guo-Hui Cai; Fu-Shan Tang; Ze-Hong Yang; Di-Shu Ao; An Zhou
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Enterolactone inhibits insulin-like growth factor-1 receptor signaling in human prostatic carcinoma PC-3 cells.

Authors:  Li-Hua Chen; Jing Fang; Zhijian Sun; Huaixing Li; Ying Wu; Wendy Demark-Wahnefried; Xu Lin
Journal:  J Nutr       Date:  2009-02-11       Impact factor: 4.798

3.  Antiangiogenic therapy effects on age-associated matrix metalloproteinase-9 (MMP-9) and insulin-like growth factor receptor-1 (IGFR-1) responses: a comparative study of prostate disorders in aged and TRAMP mice.

Authors:  Fabio Montico; Larissa Akemi Kido; Amanda Cia Hetzl; Raísa Mistieri Lorencini; Eduardo Marcelo Cândido; Valéria Helena Alves Cagnon
Journal:  Histochem Cell Biol       Date:  2014-02-22       Impact factor: 4.304

Review 4.  The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer.

Authors:  Michael W Drazer; Walter M Stadler
Journal:  Cancer J       Date:  2016 Sep/Oct       Impact factor: 3.360

5.  Periacinar retraction clefting in nonneoplastic and neoplastic prostatic glands: artifact or molecular involvement.

Authors:  Wagner José Fávaro; Amanda Cia Hetzl; Leonardo Oliveira Reis; Ubirajara Ferreira; Athanase Billis; Valéria Helena A Cagnon
Journal:  Pathol Oncol Res       Date:  2011-09-13       Impact factor: 3.201

Review 6.  Prostate cancer: the need for biomarkers and new therapeutic targets.

Authors:  Juliana Felgueiras; Joana Vieira Silva; Margarida Fardilha
Journal:  J Zhejiang Univ Sci B       Date:  2014-01       Impact factor: 3.066

7.  RelB-dependent differential radiosensitization effect of STI571 on prostate cancer cells.

Authors:  Yong Xu; Fang Fang; Yulan Sun; Daret K St Clair; William H St Clair
Journal:  Mol Cancer Ther       Date:  2010-04-06       Impact factor: 6.261

8.  Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.

Authors:  Christopher P Mill; Kathleen L Gettinger; David J Riese
Journal:  Exp Cell Res       Date:  2010-11-24       Impact factor: 3.905

9.  RelB enhances prostate cancer growth: implications for the role of the nuclear factor-kappaB alternative pathway in tumorigenicity.

Authors:  Yong Xu; Sajni Josson; Fang Fang; Terry D Oberley; Daret K St Clair; X Steven Wan; Yulan Sun; Vasudevan Bakthavatchalu; Anantharaman Muthuswamy; William H St Clair
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

Review 10.  Apoptosis by dietary agents for prevention and treatment of prostate cancer.

Authors:  Naghma Khan; Vaqar Mustafa Adhami; Hasan Mukhtar
Journal:  Endocr Relat Cancer       Date:  2010-01-29       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.